The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …

Currently approved therapies for COVID‐19 are mostly limited by their low availability, high
costs or the requirement of parenteral administration by trained medical personnel in an in …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

Background The effects of molnupiravir in treating patients with non-severe COVID-19
remain uncertain. Objectives To evaluate the efficacy and safety of molnupiravir in adult …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Introduction There are currently some differences in the research results of molnupiravir.
This study aimed to evaluate the efficacy and safety of molnupiravir in the treatment of …

Curcumin is a low‐cost and easily accessible therapeutic option for COVID‐19 patients. We
aimed to conduct a meta‐analysis to assess the effect of curcumin on clinical outcomes in …

We read with great interest the recent article by Qian et al. that reported paxlovid as an
efficacious treatment for COVID-19 patients. 1 However, the relatively high cost of paxlovid …

The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …

Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …